SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

2/14/23 12:37:58 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGEN alert in real time by email

SC 13G/A 1 rgen13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) REPLIGEN CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 759916109 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 881,136 6. Shared Voting Power* 0 7. Sole Dispositive Power* 5,070,657 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,070,657 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 9.1% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. 1. Name of Reporting Person T. ROWE PRICE NEW HORIZONS FUND, INC. 52-0791372 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 3,554,308 6. Shared Voting Power* 0 7. Sole Dispositive Power* 0 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 3,554,308 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 6.4% 12. Type of Reporting Person IV *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: REPLIGEN CORP Item 1(b) Address of Issuer's Principal Executive Offices: 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MASSACHUSETTS 02453 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) (2) T. ROWE PRICE NEW HORIZONS FUND, INC. X Attached as Exhibit A is a copy of an agreement between the Persons Filing (as specified hereinabove) that this Schedule 13G is being filed on behalf of each of them. Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland (2) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 759916109 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 X Investment Company registered under Section 8 of the Investment Company Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President T. ROWE PRICE NEW HORIZONS FUND, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2022 EXHIBIT A AGREEMENT JOINT FILING OF SCHEDULE 13G Price Associates, Inc. (an investment adviser registered under the Investment Advisers Act of 1940), and T. ROWE PRICE NEW HORIZONS FUND, INC., all of which are Maryland corporations, hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934. It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate. It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President T. ROWE PRICE NEW HORIZONS FUND, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President

Get the next $RGEN alert in real time by email

Recent Analyst Ratings for

$RGEN

Date	Price Target	Rating	Analyst
7/22/2025	$160.00	Overweight	Stephens
6/24/2025	$150.00	Overweight	Barclays
4/29/2025	$160.00	Peer Perform → Outperform	Wolfe Research
3/18/2025	$155.00	In-line	Evercore ISI
2/10/2025	$200.00	Buy	TD Cowen
12/17/2024	$165.00	Hold	Canaccord Genuity
11/14/2024		Peer Perform	Wolfe Research
8/28/2024	$180.00	Overweight	Wells Fargo

More analyst ratings

SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

2/14/23 12:37:58 PM ET

$RGEN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGEN alert in real time by email

Recent Analyst Ratings for

$RGEN

Date	Price Target	Rating	Analyst
7/22/2025	$160.00	Overweight	Stephens
6/24/2025	$150.00	Overweight	Barclays
4/29/2025	$160.00	Peer Perform → Outperform	Wolfe Research
3/18/2025	$155.00	In-line	Evercore ISI
2/10/2025	$200.00	Buy	TD Cowen
12/17/2024	$165.00	Hold	Canaccord Genuity
11/14/2024		Peer Perform	Wolfe Research
8/28/2024	$180.00	Overweight	Wells Fargo

More analyst ratings

SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RGEN

SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RGEN

$RGEN
SEC Filings

SEC Form 10-Q filed by Repligen Corporation

Repligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Repligen Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

$RGEN
Insider Trading

Director Madaus Martin D bought $201,830 worth of shares (1,800 units at $112.13) (SEC Form 4)

Director Barthelemy Nicolas was granted 973 shares, increasing direct ownership by 28% to 4,441 units (SEC Form 4)

Director Konstantinov Konstantin was granted 973 shares, increasing direct ownership by 51% to 2,894 units (SEC Form 4)

$RGEN
Press Releases

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Repligen to Report Second Quarter 2025 Financial Results

$RGEN
Insider Purchases

Director Madaus Martin D bought $201,830 worth of shares (1,800 units at $112.13) (SEC Form 4)

Director Pax Margaret bought $37,672 worth of shares (250 units at $150.69), increasing direct ownership by 32% to 1,043 units (SEC Form 4)

Director Madaus Martin D bought $201,776 worth of shares (1,615 units at $124.94) (SEC Form 4)

$RGEN
Analyst Ratings

Stephens resumed coverage on Repligen with a new price target

Barclays initiated coverage on Repligen with a new price target

Repligen upgraded by Wolfe Research with a new price target

$RGEN
Leadership Updates

908 Devices Appoints Christopher D. Brown to its Board of Directors

Repligen Appoints Jacob Johnson As Vice President Investor Relations

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

$RGEN
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Repligen Corporation

Amendment: SEC Form SC 13G/A filed by Repligen Corporation